EMA Authorised: Apexelsin (paclitaxel) — Whiteoak Pharmaceutical B.V.

View source ↗

Summary

The EMA authorised Apexelsin (paclitaxel) for breast cancer, pancreatic cancer, and non-small cell lung cancer, with Whiteoak Pharmaceutical B.V. as the marketi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Apexelsin (paclitaxel)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Pancreatic Neoplasms;Carcinoma, Non-Small-Cell Lung. MAH: Whiteoak Pharmaceutical B.V.. Decision date: 10/06/2025